Assessment of serum IGF-1 and adipokines related to metabolic dysfunction in HIV-infected adults.
OBJECTIVE
HIV/HAART associated metabolic syndrome (HAMS) seems to result from direct influence of HIV, adverse effects of combined antiretroviral therapy (cART) and individual genetic predisposition. This study aimed to assess the influence of HIV infection and cART on serum concentration of insulin-like growth factor-1 (IGF-1) and adipokines related to metabolic abnormalities.


METHODS
Seventy-two HIV infected patients including 48 HIV/HCV coinfected were enrolled in this study. Insulin resistance was evaluated by Homeostatic Model Assessment (HOMA) indexes. Serum concentrations of IGF-1, adiponectin, chemerin and visfatin were measured by ELISA.


RESULTS
Significant correlation between serum IGF-1 level and CD4 lymphocytes count was demonstrated and the lowest values were observed in subjects with CD4<200 cells/μL. Serum concentration of IGF-1 was significantly higher in patients treated with protease inhibitors based regimen compared to non-nucleoside reverse transcriptase inhibitors and healthy subjects. A significant negative correlation between serum concentration of adiponectin and waist-hip ratio as an indicator of central obesity, was found. There were significant positive correlations between serum concentration of chemerin and HOMA1-IR and serum IGF-1 concentration. Serum chemerin was increased in patients with insulin resistance vs. those with preserved insulin sensitivity.


CONCLUSIONS
According to these results HAMS is associated with insulin resistance and imbalance of adipokines serum concentration, therefore identification of pathways related to HAMS development might be helpful in management of the syndrome. Serum IGF-1 largely depends on level of immunodeficiency in HIV-infection and may provide a link between immune dysfunction and development of HIV-associated lipodystrophy, AIDS wasting syndrome, diabetes and/or cardiovascular diseases in HIV-infected patients.
Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Zurawia Str. 14, 15-540 Bialystok, Poland. Electronic address: anna.parfieniuk@gmail.com.
Anna
A
Parfieniuk-Kowerda
Sławomir Lech
SL
Czaban
Anna
A
Grzeszczuk
Jerzy
J
Jaroszewicz
Robert
R
Flisiak
D054392:Adipokines / Q000097:blood*; D052242:Adiponectin / Q000097:blood; D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism; D018925:Chemokines / Q000097:blood; D016207:Cytokines / Q000097:blood; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism; D006526:Hepatitis C / Q000097:blood* / Q000378:metabolism; D006801:Humans; D007333:Insulin Resistance; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000378:metabolism*; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood; D009765:Obesity / Q000097:blood; D012307:Risk Factors; D049629:Waist-Hip Ratio; D055815:Young Adult
D054392:Adipokines; D052242:Adiponectin; D018925:Chemokines; D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins; C478630:RARRES2 protein, human; D007334:Insulin-Like Growth Factor I; D054409:Nicotinamide Phosphoribosyltransferase; C085455:nicotinamide phosphoribosyltransferase, human
Adipokines; HCV; HIV; IGF-1; cART